BCL2 and osteosarcoma: Anti-TPD52 antiserum also reduced the expression of BCL-2 in osteosarcoma in a dose-dependent manner (ANOVA, F(5, 6) = 44.29, P = 0.0001; Fig. 7b, c), indicating that the anti-TPD52 antiserum could induce apoptosis in osteosarcoma.